Nicholas Hoffman & Company LLC. Raises Stock Position in Becton Dickinson and Co (NYSE:BDX)

Nicholas Hoffman & Company LLC. lifted its stake in shares of Becton Dickinson and Co (NYSE:BDX) by 6.9% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,048 shares of the medical instruments supplier’s stock after acquiring an additional 68 shares during the quarter. Nicholas Hoffman & Company LLC.’s holdings in Becton Dickinson and were worth $241,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. IndexIQ Advisors LLC purchased a new position in shares of Becton Dickinson and during the fourth quarter worth approximately $25,000. Verus Capital Partners LLC purchased a new position in shares of Becton Dickinson and during the fourth quarter worth approximately $27,000. Pinnacle Financial Partners Inc. purchased a new position in shares of Becton Dickinson and during the fourth quarter worth approximately $31,000. Cedar Mountain Advisors LLC purchased a new position in shares of Becton Dickinson and during the fourth quarter worth approximately $42,000. Finally, Harwood Advisory Group LLC purchased a new position in shares of Becton Dickinson and during the first quarter worth approximately $50,000. 86.79% of the stock is currently owned by institutional investors and hedge funds.

BDX traded up $0.31 during trading on Friday, hitting $239.25. The stock had a trading volume of 11,783,270 shares, compared to its average volume of 1,932,654. The company has a market capitalization of $64.79 billion, a PE ratio of 72.06, a PEG ratio of 2.57 and a beta of 0.95. Becton Dickinson and Co has a twelve month low of $197.75 and a twelve month high of $286.72. The company has a debt-to-equity ratio of 0.80, a quick ratio of 0.66 and a current ratio of 0.98. The stock has a 50 day simple moving average of $253.35 and a two-hundred day simple moving average of $255.35.

Becton Dickinson and (NYSE:BDX) last announced its earnings results on Thursday, May 7th. The medical instruments supplier reported $2.55 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.32 by $0.23. The company had revenue of $4.25 billion during the quarter, compared to the consensus estimate of $4.10 billion. Becton Dickinson and had a net margin of 6.10% and a return on equity of 15.75%. Becton Dickinson and’s revenue was up 1.4% compared to the same quarter last year. During the same period last year, the firm earned $2.59 earnings per share. On average, equities research analysts anticipate that Becton Dickinson and Co will post 10.5 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 30th. Stockholders of record on Tuesday, June 9th will be paid a dividend of $0.79 per share. The ex-dividend date is Monday, June 8th. This represents a $3.16 annualized dividend and a dividend yield of 1.32%. Becton Dickinson and’s payout ratio is currently 27.05%.

A number of equities analysts have recently issued reports on BDX shares. Barclays reiterated a “hold” rating and set a $266.00 price objective on shares of Becton Dickinson and in a research note on Tuesday, April 14th. Raymond James increased their price objective on shares of Becton Dickinson and from $283.00 to $290.00 and gave the company an “outperform” rating in a research note on Friday, May 8th. Wells Fargo & Co reiterated a “buy” rating on shares of Becton Dickinson and in a research note on Friday, May 8th. Piper Sandler increased their price objective on shares of Becton Dickinson and from $286.00 to $296.00 and gave the company an “overweight” rating in a research note on Thursday, May 14th. Finally, KeyCorp reiterated a “hold” rating on shares of Becton Dickinson and in a research note on Tuesday, May 12th. Nine analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $275.79.

Becton Dickinson and Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Featured Article: How to Invest in the Dividend Aristocrat Index

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.